Advertisement

Topics

$ABBV NDA Accepted for Priority Review by FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis. Expects regulatory decision in Q3 2019 https://www.prnewswire.com/news-releases/abbvie-announces-new-drug-application-accepted-for-pri

08:33 EST 19 Feb 2019 | Odi Bruckman

NDA Accepted for Priority Review by FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis. Expects regulatory decision in Q3 2019 https://www.prnewswire.com/news-releases/abbvie-announces-new-drug-application-accepted-for-priority-review-by-us-fda-for-upadacitinib-for-treatment-of-moderate-to-severe-rheumatoid-arthritis-300797706.html …

Original Article: $ABBV NDA Accepted for Priority Review by FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis. Expects regulatory decision in Q3 2019 https://www.prnewswire.com/news-releases/abbvie-announces-new-drug-application-accepted-for-pri

NEXT ARTICLE

More From BioPortfolio on "$ABBV NDA Accepted for Priority Review by FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis. Expects regulatory decision in Q3 2019 https://www.prnewswire.com/news-releases/abbvie-announces-new-drug-application-accepted-for-pri"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...